• Pulse Biosciences reached its enrollment target in the NANOPULSE-AF IDE pivotal study of its nPulse cardiac catheter system for atrial fibrillation.
• The trial enrolled 164 evaluable patients across 15 US clinical sites, moving the program into patient follow-up and study completion.
• No clinical results were presented in the announcement; results are expected in the future once follow-up concludes.
• Management highlighted faster-than-planned enrollment, supporting timelines for potential regulatory and commercialization milestones without disclosing efficacy outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007497622) on October 07, 2026, and is solely responsible for the information contained therein.